TY - JOUR
T1 - Future directions in the prevention of prostate cancer
AU - Thompson, Ian M.
AU - Cabang, April B.
AU - Wargovich, Michael J.
N1 - Funding Information:
The authors are supported by grants from the NCI (R01CA96994, P30CA054174 and UO1CA86402).
PY - 2014/1
Y1 - 2014/1
N2 - The high global incidence of prostate cancer has led to a focus on chemoprevention strategies to reduce the public health impact of the disease. Early studies indicating that selenium and vitamin E might protect against prostate cancer encouraged large-scale studies that produced mixed clinical results. Next-generation prostate cancer prevention trials validated the impact of 5α-reductase inhibitors in hormone-responsive prostate cancer, and these results were confirmed in follow-up studies. Other interventions on the horizon, involving both dietary and pharmacological agents, hold some promise but require further investigation to validate their efficacy. In this Review, we discuss the clinical and preclinical evidence for dietary and pharmacological prevention of prostate cancer and give an overview of future opportunities for chemoprevention.
AB - The high global incidence of prostate cancer has led to a focus on chemoprevention strategies to reduce the public health impact of the disease. Early studies indicating that selenium and vitamin E might protect against prostate cancer encouraged large-scale studies that produced mixed clinical results. Next-generation prostate cancer prevention trials validated the impact of 5α-reductase inhibitors in hormone-responsive prostate cancer, and these results were confirmed in follow-up studies. Other interventions on the horizon, involving both dietary and pharmacological agents, hold some promise but require further investigation to validate their efficacy. In this Review, we discuss the clinical and preclinical evidence for dietary and pharmacological prevention of prostate cancer and give an overview of future opportunities for chemoprevention.
UR - http://www.scopus.com/inward/record.url?scp=84890984850&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84890984850&partnerID=8YFLogxK
U2 - 10.1038/nrclinonc.2013.211
DO - 10.1038/nrclinonc.2013.211
M3 - Review article
C2 - 24281061
AN - SCOPUS:84890984850
SN - 1759-4774
VL - 11
SP - 49
EP - 60
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 1
ER -